MarketPulse
G

$GMAB

6 articles found
1 positive
0 negative
5 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

BsADC Market Set to Reach $2B by 2030 as First Drug Approval Looms

Bispecific antibody drug conjugates market projected at $2B+ by 2030, with first approval expected by 2028 amid 150+ global clinical trials.
AMGNAZNGMABclinical trialsmarket opportunity
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Bispecific Antibodies Poised for $60B Market by 2031 as 550+ Trials Reshape Therapeutics

Bispecific antibody market projected to reach $60 billion by 2031 from $16 billion in 2025, with 550+ clinical trials and 18 approved drugs driving sector transformation.
AMGNJNJPFEABBVRHHBY+3clinical trialsautoimmune diseases
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Genmab Completes Share Buyback Program With 1.9M Treasury Share Cancellation

Genmab cancels 1.9M treasury shares, reducing DKK share capital by 3% effective April 2026. Nasdaq updates expected by April 21.
GMABshare capital reductiontreasury shares
GlobeNewswire Inc.GlobeNewswire Inc.··Genmab A/S

Orbis Investment Management Builds 4.99% Stake in Danish Biotech Giant Genmab

Orbis Investment Management discloses 4.99% stake in Genmab A/S, holding 3.2M shares, signaling institutional confidence in the Danish biotech firm's strategy.
GMABAnnual General Meetingbiotechnology
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Genmab Corrects Executive Share Transaction, Reveals DKK 1,867.50 Pricing

Genmab corrects insider transaction report, fixing share price from DKK 0.00 to DKK 1,867.50 for executive RSU settlement.
GMABrestricted stock unitsexecutive compensation
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Genmab Executives Settle RSUs Worth Millions in Deferred Bonus Vesting

Genmab A/S disclosed RSU vesting for top executives as part of deferred bonus arrangements, triggering mandatory insider trading disclosures under EU regulations.
GMABrestricted stock unitsMarket Abuse Regulation